ArticleNature2021
Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection.
Abstract read
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 478 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
478citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
478 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global prevalence of post-COVID-19 condition: a systematic review and meta-analysis of prospective evidence.Health promotion and chronic disease prevention in Canada : research, policy and practice · 2025Pooled it
- SARS-CoV-2 convalescent plasma for the controlled clinical trial "COVIC-19": Experience from collection of very high-titer plasma from superimmunized individuals.Transfusion · 2025Trial
- Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trial.EBioMedicine · 2025Trial
- Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study.Scientific reports · 2024Trial
- Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial.Nature medicine · 2023Trial
- One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients.The Journal of clinical investigation · 2022Trial
- Titers and breadth of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: A single-blinded, randomized clinical trial.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2022Trial
- A targeted metabolic intervention via exercise applied after vaccination shapes kinetics and durability of serum antibody accompanied by a distinct immunometabolic signature: pilot study.Brain, behavior, & immunity - health · 2026Article
- R1-32-like public antibodies acquire tolerance to SARS-CoV-2 antigenic drift through somatic hypermutation.PLoS biology · 2026Article
- Article
- Charge-driven antiviral responses enhance autoreactivity in severe COVID-19.Research square · 2026Article
- Somatic Evolution of a Germline Antibody Expands its Breadth to Neutralize Early SARS-CoV-2 Omicron Variants.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- mRNA delivery of a class 1/4 SARS-CoV-2 neutralizing antibody protects against diverse sarbecoviruses in a lethal mouse challenge model.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Multiplexed antigen panel analysis identifies B cell phenotype and receptor genetic contributions to antibody breadth.Immunity · 2026Article
- Use of the test-negative design to estimate the protective effect of a scalar immune measure: a simulation analysis.American journal of epidemiology · 2026Article
- Immunological memory to vaccines.Immunity · 2026Review
- A SARS-CoV-2 variant-induced NTD-targeting antibody enhances viral infection via a distinctive binding mode.PLoS pathogens · 2026Article
- Impact of adjuvants on a recombinant SARS-CoV-2 spike vaccine: Protective efficacy and recall antibody response following homologous challenge.Biosafety and health · 2026Article
- Heterologous immunization modulates B-cell epitope competition between helper peptides and the MPER segment in MPER/liposome vaccines.NPJ vaccines · 2026Article
- Memory B cell development in response to mRNA SARS-CoV-2 and nanoparticle immunization in mice.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
418 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Update of
Authors and funding
28 authors.
Zijun Wang *Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Frauke Muecksch *Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0002-0132-5101
Dennis Schaefer-Babajew *Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0002-5380-2950
Shlomo Finkin *Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0003-4474-2658
Charlotte Viant *Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Christian Gaebler *Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0001-7295-8128
Hans- Heinrich HoffmannLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
Christopher O BarnesDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
Melissa CipollaLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Victor RamosLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0001-7353-3420
Thiago Y OliveiraLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0002-2654-0879
Alice ChoLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Fabian SchmidtLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
Justin Da SilvaLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
Eva BednarskiLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
Lauren AguadoLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0002-0036-4803
Jim YeeDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0003-1595-6585
Mridushi DagaLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Martina TurrojaLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0001-9640-0559
Katrina G MillardLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0003-2247-3178
Mila JankovicLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Anna GazumyanLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Zhen ZhaoDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-9742-5982
Charles M RiceLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
Paul D BieniaszLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA. pbieniasz@rockefeller.edu.ORCID http://orcid.org/0000-0002-2368-3719
Marina CaskeyLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. mcaskey@rockefeller.edu.ORCID http://orcid.org/0000-0003-1727-8693
Theodora HatziioannouLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA. thatziio@rockefeller.edu.ORCID http://orcid.org/0000-0002-7889-0766
Michel C NussenzweigLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. nussen@rockefeller.edu.ORCID http://orcid.org/0000-0003-0592-8564
Funding
Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6MUnderstanding B cell memory in response to diverse virus infectionsU19AI111825 · NIAID · ROCKEFELLER UNIVERSITY · PI RAVETCH, JEFFREY VICTOR · 2014 to 2023
$26.0MOvercoming Host Restriction Factors to Develop Better Animal Models for HIV/AIDS.R01AI078788 · NIAID · ROCKEFELLER UNIVERSITY · PI HATZIIOANNOU, THEODORA · 2008 to 2021
$9.3MType I interferon-stimulated genes and the antiviral immune responseR01AI091707 · NIAID · ROCKEFELLER UNIVERSITY · PI RICE, CHARLES M · 2011 to 2020
$5.5MDiscovery and Mechanism of Antiretroviral FactorsR37AI064003 · NIAID · ROCKEFELLER UNIVERSITY · PI BIENIASZ, PAUL D. · 2011 to 2020
$4.9MHoward Hughes Medical InstituteNCATS NIH HHS UL1 TR001866NIAID NIH HHS R01 AI078788NIAID NIH HHS R01 AI091707NIAID NIH HHS R37 AI064003NIAID NIH HHS U19 AI111825NIH HHS 2U19 AI111825NIH HHS P01 AI138398-S1Wellcome Trust
Abstract
More than one year after its inception, the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains difficult to control despite the availability of several working vaccines. Progress in controlling the pandemic is slowed by the emergence of variants that appear to be more transmissible and more resistant to antibodies
Indexed as
AdultAgedAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralB-LymphocytesCOVID-19Enzyme-Linked Immunosorbent AssayEpitopesFemaleHumansImmunologic MemoryMaleMiddle AgedSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralEpitopesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.